Ledipasvir Medications

Ledipasvir Info

What is Ledipasvir?

Ledipasvir belongs to a class of medicines called direct-acting antiviral agents. It works against the hepatitis C virus (HCV) by stopping the virus from multiplying inside liver cells. Because it targets a specific part of the virus, it can clear an infection when used in the right combination.

Medications that contain Ledipasvir

The most common product that includes ledipasvir in Hong Kong is Harvoni. Harvoni is a fixed-dose tablet that combines ledipasvir with another antiviral called sofosbuvir. The tablets are available in two strengths: 90 mg ledipasvir / 400 mg sofosbuvir and 90 mg ledipasvir / 400 mg sofosbuvir (often marketed as Harvoni 90/400). Both the generic and branded versions are approved by the Hong Kong Department of Health’s Drug Office and can be obtained with a prescription from a qualified practitioner.

What does Ledipasvir treat?

Ledipasvir is used as part of a combination therapy for chronic hepatitis C infection. The key conditions it helps manage are:

• Chronic hepatitis C (HCV) infection - an illness that can cause liver inflammation, scarring (cirrhosis) and, over many years, liver cancer.
• Different HCV genotypes - ledipasvir is most effective against genotype 1, the most common strain in Hong Kong, but the combination with sofosbuvir also covers some other genotypes.
• Patients with compensated liver disease - people whose liver is still functioning reasonably well, allowing the medication to clear the virus without causing further liver damage.

These uses are authorised by the Hong Kong health authorities. While ledipasvir is principally approved for HCV, doctors may occasionally consider it for special cases where the virus shows resistance to other treatments, though such decisions are made on an individual basis.

How does Ledipasvir work?

Ledipasvir blocks a protein on the hepatitis C virus called NS5A. This protein helps the virus assemble and release new viral particles. By inhibiting NS5A, ledipasvir prevents the virus from completing its life cycle, which reduces the amount of virus in the blood. When the viral load drops sufficiently, the immune system can clear the remaining infection. The effect is usually noticeable within a few weeks of starting treatment, but the full course should be completed as prescribed to achieve a cure.

Safety information

Common side effects

• Mild headache
• Fatigue or feeling unusually tired
• Nausea or mild stomach upset

These reactions are usually temporary and resolve without medical intervention. If they persist or become bothersome, patients should seek advice from a qualified health professional.

Serious reactions

• Allergic reactions - swelling of the face, lips, tongue, or throat, or a rash that spreads quickly may signal an allergy.
• Liver issues - although rare, signs such as yellowing of the skin or eyes (jaundice), dark urine, or severe abdominal pain require urgent medical attention.

If any of these symptoms appear, seek emergency help promptly.

Who should be cautious

• Pregnant or breastfeeding individuals - the safety of ledipasvir during pregnancy has not been fully established, so it is generally avoided unless the benefits clearly outweigh the risks.
• People with severe liver impairment - the drug may need special monitoring, as liver function influences how the medication is processed.
• Individuals with known hypersensitivity to ledipasvir or any ingredient in Harvoni should not take the product.

Interaction awareness

• Other medicines - certain drugs that affect the liver enzyme system (for example, some antiretrovirals, anticonvulsants, and certain antibiotics) can alter ledipasvir levels.
• Alcohol - excessive drinking can worsen liver disease and may reduce the effectiveness of treatment.
• Food - Harvoni can be taken with or without food; however, high-fat meals may slightly increase absorption, which the prescribing doctor will consider.

For a full list of possible interactions, refer to the specific medication’s information leaflet.

What to know before using

Store Harvoni tablets at room temperature, away from direct sunlight and moisture. Keep them out of reach of children. The usual treatment course for chronic hepatitis C is several weeks, but exact duration varies with the individual’s virus genotype and liver condition. Always follow the instructions that come with your specific tablet and keep any follow-up appointments for blood tests that monitor viral load and liver function.

Key terms

Hepatitis C virus (HCV): A virus that infects the liver and can cause long-term damage if not cleared.

Genotype: A classification of the hepatitis C virus based on its genetic makeup; different genotypes respond differently to treatment.

Viral load: The amount of hepatitis C virus present in the blood, measured to assess how well treatment is working.

Information disclaimer

This article offers general educational information about ledipasvir as an active substance used in various medicines. Its purpose is to help patients better understand the ingredient and the conditions it is used to treat. It is not a substitute for professional medical advice or for the specific instructions provided with individual products. Medicines containing ledipasvir may differ in formulation, strength, and directions for use. Always consult the labeling of your particular medication and follow your healthcare provider’s guidance for complete information on proper use, dosage, and safety.